Last reviewed · How we verify

NCT04187586

Effect of Extracorporeal Shock Wave Therapy for Burn Scar Charateristics

Completed Last updated 16 December 2019
What this trial tests

trial testing Extracorporeal shock wave therapy in Burn Scar in 35 participants. Completed in 12 December 2019.

Timeline
10 December 2019
Primary endpoint
12 December 2019
12 December 2019

Quick facts

Lead sponsorHangang Sacred Heart Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment35
Start date10 December 2019
Primary completion12 December 2019
Estimated completion12 December 2019
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Hangang Sacred Heart Hospital

Who can join

Adults 18 to 70, any sex, with Burn Scar. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

No study has investigated the effect of extracorporeal shock wave therapy (ESWT) on hypertrophic scar characteristics. Thus, this study aimed to ascertain the effects ESWT on burn scars. The investigators retrospectively reviewed burn patients who had undergone autologous split-thickness skin grafting (STSG) with same artificial dermis between January 2012 and September 2019.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Measurement of Transepidermal Water Loss.
    Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other trials of Extracorporeal shock wave therapy

Trials testing the same drug.

Other recruiting trials for Burn Scar

Currently open trials in the same condition.

Other Hangang Sacred Heart Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04187586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing